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INTERLEUKIN-18  (IL-18),  a  pro-inflammatory  cytokine
that plays an important role in the T-cell-helper type
1  response,  is  a  new  member  of  the  family  of
cytokines produced in the brain. CD30 is a marker of
T-cell-helper type 2 lymphocytes. We evaluated IL-18
and  CD30  serum  levels  in  10  patients  affected  by
moderate-severe depression (MSD). We demonstrated
for  the  first  time  that  serum  IL-18  levels  of  MSD
patients  were  significantly  higher  than  those  of
healthy  donors.  On  the  contrary,  no  significant
difference was found between serum CD30 levels of
MSD patients compared with those of healthy donors.
These data strengthen the hypothesis that MSD dis-
ease  is  associated  with  an  inflammatory  response,
mainly T-cell-helper type 1, and suggest an important
role for IL-18 in the pathophysiology of MSD.
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It has been documented that there is a strong inter-
relationship between the immune system, the central
nervous system and psychological process.1
Cytokines  are  mostly  glycoproteins  that  play  a
crucial role in cell-to-cell signalling. Furthermore, in
providing  communication  between  immune  cells,
specific cytokines play a role in signalling the brain to
produce  neuroimmune,  neurochemical,  neuroendo-
crine  and  behavioural  changes.1 The  cytokines  are
actively transported into the central nervous system
where activate glia cells produce other cytokines, and
a cascade of cytokine effects may be initiated by this
mechanism.1
The production of cytokines in  the brain  occurs
following brain system irritation, infection, injury or
ischaemia, or in response to various stresses such as
anxiety  or  depression.1 In  particular,  depression
represents a major public  health problem. There is
now some evidence that depression may be accom-
panied by an immune response. The plasma concen-
tration of pro-inflammatory cytokines has been repor-
ted as elevated in depressed patients, and in healthy
persons on stress.1
Interleukin-18  (IL-18),  also  called  interferon-
g-inducing factor, is a pro-inflammatory cytokine that
plays  an  important  role  in  the T-cell-helper  type  1
(Th1) response. IL-18 may contribute to inflammation
because it is a potent inducer of gene expression and
synthesis of tumour necrosis factor, IL-1, Fas ligand,
and  several  chemokines.2 Conti  et  al. demonstrate
that microglia and astrocytes are sources of brain IL-
18 and add a new member to the family of cytokines
produced in the brain.3
IL-18 is also proposed to have a role in modulating
immune function during immunological disturbances.
In  particular,  an  inappropriate  production  of  this
cytokine is known to be involved in schizophrenia. In
fact, serum IL-18 levels are elevated in schizophrenic
patients.3
CD30 is a member of the tumour necrosis factor-
nerve  growth  receptor  superfamily,  existent  as  a
membrane glycoprotein of 105 and 120kDa, derived
from  a  90kDa precursor and a 57kDa intracellular
form. CD30 is a marker of activated T-cell-helper type
2 (Th2) lymphocytes. There is also an 88kDa soluble
form  of  CD30 (sCD30),  which originated from  the
proteolytic  cleavage  of  the  extracellular  portion  of
sCD30, released by CD30+ cells.4
In light of these findings, since at present there are
no  data  about  IL-18  and  CD30  release  on  patients
affected by depression disease, we investigated in this
preliminary study a possible role for these molecules
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sion (MSD). In particular, we evaluated the presence
of IL-18 and sCD30 in sera of patients affected by MSD
before anti-depression drug administration.
To this end, we enrolled 10 patients (all females)
affected  by  MSD  in  this  study  (mean  age,  38.60  ±
14.68 years; range, 21–60 years) who experienced a
major  depressive episode according to  DSM-IV  cri-
teria  recruited  from  the  Outpatient  Mental  Health
Service  of  the  Department  of  Neurosciences,  Psy-
chiatry  and  Anesthesiology.  Mood  was  assessed  at
baseline  by  using  the  Beck  Depression  Inventory
(range, 0–63). The mean baseline score of the Beck
Depression  Inventory  is  28.1  (standard  deviation,
8.8),  varying  from  20  to  43.  Ten  healthy  females
(mean age, 36.92 ± 13.50; range, 22–54 years) were
also  enrolled  as  the  control  group.  Patients  and
healthy  donors  (HD)  signed  an  informed  consent
form.
Sera were obtained from peripheral blood allowed
to  clot  at  room  temperature  for  2h,  separated  by
centrifugation at 200 ´ g for 15min in a 4235 A (ALC
Int. S.r.L., Milan, Italy) centrifuge, and stored at –80°C
until use.
Serum  IL-18  was  assayed  by  immunoenzymatic
methods  (Quantikine  Human  IL-18,  R&D  System;
SPACE  Import–Export,  Milan,  Italy). The  detection
limit for IL-18 was 12.5pg/ml.
Serum  sCD30  levels  were  determined  by  the
commercial  sandwich ELISA Dako CD30 (Ki-1  anti-
gen; Dako, Milan, Italy). The limit of detection of the
assay was 1IU/ml.
Differences in serum levels were assessed by one-
way analysis of variance and the Student–Newman–
Keults test. Data are expressed as the mean ± standard
deviation. p < 0.05 was considered significant.
Serum  IL-18  levels  of  MSD  patients  were  sig-
nificantly higher than those of HD (568.99 ± 260.18
versus  319.00  ±  72.31,  p <  0.05)  (Fig.  1).  On  the
contrary, no significant difference was found between
serum sCD30 levels of patients compared with those
of HD; in fact, all subjects had sCD30 values < 1IU/
ml.
There is  clinical  and  experimental  evidence  that
activation of the brain cytokine system is associated
with  depression,  although  the  exact  relationship
between  sickness  behaviour  and  depression  is  still
elusive.1
The results of the present preliminary study, which
is  the  first  to  investigate  circulating  IL-18  levels  in
MSD disease, show higher levels of this cytokine in
patients affected by this disease than HD. Our data
support the demonstration, reported by many inves-
tigators, that the depression disease is characterized
by increased activity immune response and that the
systemic  immune  stimulation  participates  in  the
pathophysiology  or  pathogenesis of  the  depression
disease.1
According to previous studies,1 we may hypothe-
size that, as other pro-inflammatory cytokines, IL-18
may  stimulate  the  hypothalamic–pituitary–adrenal
axis and enhance sympathetic nerve system activity,
suggesting a pivotal role in psychological process and
psychiatric disorders. These results represent the first
evidence  in  MSD  disease  of  IL-18  involvement,  a
cytokine  that  promotes Th1  responses;  supporting
the hypothesis that this disease is associated with an
activation of  inflammatory response, mainly  of Th1
type. This hypothesis is strengthened by our results:
in fact, no significant difference was found between
serum sCD30 levels of MSD patients compared with
those of HD. CD30 is expressed only by activated Th2
cells.2
Moreover, it has been reported that IL-18 is highly
involved  in  the  pathogenesis  of  cardiovascular dis-
eases.5 In  fact,  circulating  levels  of  IL-18  reflect
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FIG. 1. IL-18 serum levels in patients affected by moderate-severe depression and in healthy donors.aetiologies  of  heart  failure.  A  Th1/Th2  cytokine
imbalance  exaggerates  the  pathophysiology  of
advanced heart failure.5 Then, the high IL-18 serum
levels reported in this preliminary study, during MSD
disease, may partially explain the increase of cardio-
vascular risks that occur frequently  among patients
with depression disease.
In conclusion, our preliminary findings suggest an
important  role  for  IL-18  in  the  pathophysiology  of
MSD disease and provide a direction for more specific
immunomodulating therapy.
ACKNOWLEDGEMENTS. This work was supported in part by a grant from
University of Messina Medical School, Italy.
References
1. Maes M. Evidence for an immune response in major depression: a review
and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatr 1995; 19:
11–38.
2. D’Elios MM, Romagnani P, Scaletti C. In vivo CD30 expression in human
disease with predominant activation of Th2-like T  cells. J Leukoc Biol
1997; 61: 539–544.
3. Conti B, Park LC, Calingasan NY, et al. Cultures of astrocytes and microglia
express interleukin-18. Brain Res Mol Brain Res 1999; 67: 46–52.
4. Tanaka KF, Shintani F, Fujii Y, et al. Serum interleukin-18 levels are elevated
in schizophrenia. Psychiatry Res 2000; 96: 75–80
5. Yamaoka-TojoM, Tojo T, Inomata T, et al. Circulating levels of interleukin-
18  reflect  etiologies  of  heart  failure:  Th1/Th2  cytokine  imbalance
exaggerates the pathophysiology of advanced heart failure. J Cardiac Fail
2002; 8: 21–27.
Received 10 April 2002
Accepted 2 April 2002
IL-18 and sCD30 in moderate-severe depression disease
Mediators of Inflammation · Vol 11 · 2002 267